Portola Pharmaceuticals Inc (PTLA) - Financial and Strategic SWOT Analysis Review

  • ID: 4278641
  • SWOT Analysis
  • 48 pages
  • GlobalData
1 of 5
Portola Pharmaceuticals Inc (PTLA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Portola Pharmaceuticals Inc (Portola Pharmaceuticals) is a biopharmaceutical company which conducts research to develop therapeutics in the areas of thrombosis, other hematologic disorders and inflammation. The company's products portfolio include Betrixaban, an oral once-daily Factor Xa inhibitor anticoagulant that inhibits the activity of Factor Xa; andexanet alfa, a recombinant protein designed to reverse anticoagulant activity of both direct and indirect Factor Xa inhibitors; and cerdulatinib, an oral, dual Syk-JAK inhibitor in development to treat hematologic cancers. Portola Pharmaceuticals provides compounds using biomarker and genetic approaches for clinical, regulatory and commercial purpose of life-saving therapies . The company works in collaboration with other pharmaceutical and biotechnology companies for the clinical development of its lead candidates. Portola Pharmaceuticals is headquartered in South San Francisco, California, the US.

Portola Pharmaceuticals Inc Key Recent Developments

Jun 25, 2018: Portola Pharmaceuticals Names Glenn Brame as Senior Vice President of Technical Operations
Jun 04, 2018: Portola Pharmaceuticals Announces Retirement of CEO Bill Lis in 2018
May 09, 2018: Portola Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
Mar 12, 2018: Portola Pharmaceuticals Appoints Biotech Legal Veteran John Moriarty as Executive Vice President and General Counsel
Feb 28, 2018: Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5
Section 1 - About the Company
  • Portola Pharmaceuticals Inc - Key Facts
  • Portola Pharmaceuticals Inc - Key Employees
  • Portola Pharmaceuticals Inc - Key Employee Biographies
  • Portola Pharmaceuticals Inc - Major Products and Services
  • Portola Pharmaceuticals Inc - History
  • Portola Pharmaceuticals Inc - Company Statement
  • Portola Pharmaceuticals Inc - Locations And Subsidiaries
  • Head Office
Section 2 - Company Analysis
  • Company Overview
  • Portola Pharmaceuticals Inc - Business Description
  • R&D Overview
  • Portola Pharmaceuticals Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Portola Pharmaceuticals Inc - Strengths
  • Portola Pharmaceuticals Inc - Weaknesses
  • Portola Pharmaceuticals Inc - Opportunities
  • Portola Pharmaceuticals Inc - Threats
  • Portola Pharmaceuticals Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Portola Pharmaceuticals Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Jun 04, 2018: Portola Pharmaceuticals Announces Retirement of CEO Bill Lis in 2018
  • May 09, 2018: Portola Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
  • Mar 12, 2018: Portola Pharmaceuticals Appoints Biotech Legal Veteran John Moriarty as Executive Vice President and General Counsel
  • Feb 28, 2018: Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
  • Dec 22, 2017: Portola Pharmaceuticals to Webcast Corporate Update on January 9, 2018
  • Nov 06, 2017: Portola Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
  • Nov 06, 2017: Portola Pharmaceuticals Appoints Industry Veteran John H. Lawrence, M.D., as Senior Vice President and Chief Medical Officer
  • Aug 09, 2017: Portola Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
  • May 08, 2017: Portola Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
  • Feb 28, 2017: Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Portola Pharmaceuticals Inc, Key Facts
  • Portola Pharmaceuticals Inc, Key Employees
  • Portola Pharmaceuticals Inc, Key Employee Biographies
  • Portola Pharmaceuticals Inc, Major Products and Services
  • Portola Pharmaceuticals Inc, History
  • Portola Pharmaceuticals Inc, Key Competitors
  • Portola Pharmaceuticals Inc, Ratios based on current share price
  • Portola Pharmaceuticals Inc, Annual Ratios
  • Portola Pharmaceuticals Inc, Annual Ratios (Cont...1)
  • Portola Pharmaceuticals Inc, Annual Ratios (Cont...2)
  • Portola Pharmaceuticals Inc, Interim Ratios
  • Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Portola Pharmaceuticals Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Portola Pharmaceuticals Inc, Performance Chart (2013 - 2017)
  • Portola Pharmaceuticals Inc, Ratio Charts
  • Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Xencor Inc
  • SELLAS Life Sciences Group Inc
  • KemPharm Inc
  • Inotek Pharmaceuticals Corp
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll